References
1. Solorzano GE, Phillips LH, 2nd. Inclusion body myositis: diagnosis,
pathogenesis, and treatment options. Rheum Dis Clin North Am.
2011;37(2):173-83, v.
2. AlJohani NI, Carette S, Lipton JH. Inclusion body myositis in a
patient with chronic myeloid leukemia treated with dasatinib: a case
report. J Med Case Rep. 2015;9:214.
3. Naddaf E, Shelly S, Mandrekar J, Chamberlain AM, Hoffman EM, Ernste
FC, et al. Survival and associated comorbidities in inclusion body
myositis. Rheumatology (Oxford). 2021.
4. Greenberg SA. Inclusion body myositis: clinical features and
pathogenesis. Nat Rev Rheumatol. 2019;15(5):257-72.
5. Naddaf E, Barohn RJ, Dimachkie MM. Inclusion Body Myositis: Update on
Pathogenesis and Treatment. Neurotherapeutics. 2018;15(4):995-1005.
6. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - a
review on pharmacology, metabolism and side effects. Curr Drug Metab.
2009;10(5):470-81.